Obio Launches Gmp Production Facility Intelli-M to Expedite Innovative and Advanced Therapies to Patients Who Are in Need
Intelli-M is up and running in manufacturing Phase III CGT products for clients. With the addition of this state-of-the-art and GMP-compliant clinical manufacturing facility, and OBiO's specialized expertise in viral vectors (such as AAV and LVV, the most commonly used vectors), oncolytic virus, plasmids and mRNA, OBiO is positioned to enhance its CGT business and integrated end-to-end solutions for global customers. Intelli-M site is equipped with a range of single-use bioreactors from 50 to 2000 liters and closed downstream processing, providing flexible scales to tailor customer's needs. By leveraging cutting-edge and proprietary technologies, this facility expands OBIO's process development and GMP manufacturing capabilities. Equipped with intelligent robotic feeding system, automated filling system, fully automated liquid nitrogen storage system, cleanroom automation chip management, remotely accessible electronic signature systems, and full-lifecycle project visibility, OBiO is on its track to enhance operational efficiency and reduce delivery timelines, becoming a leading global CDMO to expedite clients' CGT to patients.